Alvotech Projects Strong Q4 Growth and Sets Annual Revenue Targets Amid Pending FDA Approvals
Alvotech (ALVO) has issued optimistic financial guidance, targeting annual revenue between $650 million and $700 million, with an expected EBITDA in the range of $180 million to $220 million. Management anticipates that the fourth quarter will be the strongest in the company's history. The company is currently awaiting critical regulatory decisions from the FDA regarding three products. Executive Chairman Robert Wessman highlighted AVT05 as a key catalyst with significant market potential, noting that approvals are expected before the end of the year.
Tickers: $ALVO